Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Charles River Laboratories consensus in focus, shares under Wall Street scrutiny - Ad-hoc-news.de

AI-generated analysis

📈 Charles River Laboratories reported Q1 2026 EPS of $2.06, beating the consensus estimate of $1.96.

🏢 Morgan Stanley upgraded its stance on CRL citing improved biopharma funding and strong medium-term demand.

⚖️ Zacks Investment Research compares CRL to Labcorp Holding (LH), favoring LH on forward valuation metrics.

💰 Stock price is approximately $183.79 with a market cap of roughly $8.9 billion as of June 23, 2026.

📉 Year-to-date performance shows a decline of about 10.3% despite a twelve-month gain of over 23%.

🌍 The company provides preclinical and clinical research services across North America, Europe, and Asia.

🔬 Business scope includes early-stage drug discovery, safety assessment, and laboratory services for regulatory submission.

📊 CRL is a member of the S&P 400 MidCap index within the Healthcare - Life Sciences Tools & Services sector.

Bullish Signals
  • Q1 2026 earnings per share of $2.06 exceeded the consensus estimate of $1.96, indicating solid operational performance.
  • Morgan Stanley upgraded its stance on Charles River Laboratories, identifying it as a relative beneficiary of improved biopharma funding.
  • The company is positioned to benefit from a stronger medium-term demand backdrop for contract research services.
  • Shares have achieved a twelve-month performance of over 23%, outperforming several smaller peers in the professional services sector.
Risk Factors
  • Zacks Investment Research argues that Labcorp Holding (LH) offers stronger value metrics on earnings and price-based ratios compared to CRL.
  • Year-to-date performance has been negative at approximately minus 10.3%, contrasting with the twelve-month gain.
  • The stock exhibits a volatile trading pattern in 2026, suggesting potential short-term instability despite long-term gains.
Full Analysis
Charles River Laboratories International (CRL) is currently under Wall Street scrutiny as analysts remain divided on its valuation and earnings outlook. The company recently reported first-quarter 2026 earnings on May 7, beating consensus estimates with EPS of $2.06 versus the expected $1.96. This beat supports a fundamental view among analysts, though recent trading patterns have shown volatility. Morgan Stanley has upgraded its stance on Charles River, viewing it as a beneficiary of improved biopharma funding and stronger medium-term demand for contract research services. Conversely, Zacks Investment Research compares CRL closely with Labcorp Holding (LH), arguing that LH currently offers stronger value metrics regarding earnings and price-based ratios, particularly in forward valuation. As of June 23, 2026, CRL shares trade around $183.79 with a market capitalization of approximately $8.9 billion. The stock has delivered over 23% year-to-date performance but is down about 10.3% year-to-date in the current session context, reflecting a volatile trading pattern in 2026. The company operates globally providing preclinical and clinical research services to pharmaceutical and biotech clients.